Tocilizumab

Catalog No.A2012 Synonyms: MRA Non-humanized mouse model applicable

For research use only. Not for use in humans.

Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

Size Price Stock Quantity  
USD 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Quality Control

Choose Selective IL Receptor Inhibitors

Biological Activity

Description Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
Targets
IL-6R [1]
()
In vitro

Tocilizumab inhibits the binding of IL-6 to its receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the human IL-6 receptor. The inhibitory profile of anti-IL-6R mAb Tocilizumab is independent of membrane-bound IL-6R expression[1]. Tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator. It has also been demonstrated that tocilizumab has an anti-proliferative effect on glioma cells via inhibition of the JAK-STAT3 pathway. Tocilizumab exhibits a significant growth inhibition in NSCLC cells (H460, A549, H1299 and H358), with proliferation significantly decreased by approximately 40% in A549 cells. Tocilizumab does not alter the levels of the ERK1/2, STAT3, NFκB and phosphorylated ERK1/2 and STAT3 proteins, but this antibody does considerably increase the expression of phosphorylated NFκB in NSCLC cells[2]. Tocilizumab significantly inhibits expression of both IL-8 and MMP-9, known as the major angiogenic factors[3].

In vivo A series of clinical studies has shown that inhibition of IL-6 signaling by tocilizumab is therapeutically effective in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease. In all of these diseases, tocilizumab ameliorates inflammatory manifestations, and normalizes acute phase protein levels. Tocilizumab as a monotherapy and in combination, such as with methotrexate in case of rheumatoid arthritis, seems to be well tolerated. Tocilizumab markedly decreases the number of invaded capillary vessels in tumors. In addition, tocilizumab shows almost no effect on mitogenic rate and apoptosis of tumor cells[3].

Protocol

Cell Research:
+ Expand
  • Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function
    Cells: HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)
    Concentrations: 5 μg/ml
    Incubation Time: 72 h
    Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253315/

    Objective: Effect of tocilizumab on the growth of Lung Cancer Cells
    Cells: human-derived HARA-B cells
    Concentrations: 1, 10, 100 ng/ml
    Incubation Time: 48 h
    Method: HARA-B cells were cultured for 24 h in DMEM, then in serum-free DMEM for 24 h and then for 48 h in HACM (serum-free), with or without tocilizumab (1, 10, and 100 ng/mL) or human IgG as the negative control.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565278/

    Tocilizumab can apply to immunodeficient mice (eg: SCID mice), Non-immunodeficient mice (eg: DBA/1J mice), various cancer cell lines and other in vitro assays (Only for Reference)
Animal Research:
+ Expand
  • Objective: Tocilizumab inhibits the growth of mucoepidermoid carcinomas
    Animal Models: Female severe combined immunodeficient (SCID) mice were transplanted with Michigan-Human Mucoepidermoid Carcinoma cells
    Formulation: --
    Dosages: 5 mg/kg
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/26287605

    Objective: Therapeutic assessment of Tocilizumab-Alendronate Conjugate in collagen-induced arthritis (CIA) mice model
    Animal Models: DBA/1j mice were injected with CII which emulsified in CFA or IFA
    Formulation: PBS
    Dosages: 0.8 mg/kg
    Administration: Locally injected on the arthritic ankle joints
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/28107624

    Tocilizumab can apply to immunodeficient mice (eg: SCID mice), Non-immunodeficient mice (eg: DBA/1J mice), various cancer cell lines and other in vitro assays (Only for Reference)

Product Details

Formulation PBS buffer, pH 7.2
Isotype Human IgG
Source CHO cells
Storage Store at -80°C and avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related IL Receptor Products

Tags: buy Tocilizumab | Tocilizumab supplier | purchase Tocilizumab | Tocilizumab cost | Tocilizumab manufacturer | order Tocilizumab | Tocilizumab distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID